Recent news on Palonosetron Hydrochloride

MGI PHARMA to Present at the Bank of America Healthcare Conference  -  May 24, 2007
Insurance News Net,MGI PHARMA markets Aloxi(R) (palonosetron hydrochloride) Injection, Dacogen(R) (decitabine) for Injection and Gliadel(R) Wafer (polifeprosan 20 with

HELSINN Announces Submission of Supplemental New Drug Application ...  -  May 7, 2007
PR-Inside.com (Pressemitteilung),...today announced that a supplemental New Drug Application (sNDA) for Aloxi(R) (palonosetron hydrochloride) Injection for the prevention of Post-Operative

MGI Pharma seeks broader market for anti-nausea drug  -  May 7, 2007
Twin Cities Business Journal,Helsinn Healthcare, a privately owned Swiss pharmaceutical group that licenses some of the ingredients of Aloxi (palonosetron hydrochloride).

MGI Pharma First Quarter 2007 Financial Results Conference Call to ...  -  Apr 11, 2007
PharmaLive.com (press release),MGI PHARMA markets Aloxi(R) (palonosetron hydrochloride) Injection, Dacogen(R) (decitabine) for Injection and Gliadel(R) Wafer (polifeprosan 20 with

MGI PHARMA First Quarter 2007 Financial Results Conference Call to ...  -  Apr 11, 2007
Business Wire (press release),MGI PHARMA markets Aloxi® (palonosetron hydrochloride) Injection, Dacogen® (decitabine) for Injection and Gliadel® Wafer (polifeprosan 20 with carmustine

MGI PHARMA Reports First Quarter 2007 Financial Results  -  Apr 19, 2007
PharmaLive.com (press release),During the first quarter of 2007, US sales of Aloxi(R) (palonosetron hydrochloride) Injection totaled $47.3 million compared to $63.3 million in the first

Rebecca Dop Completes Certified Trade Show Marketer (CTSM) Program  -  Mar 21, 2007
Exhibitor Online,MGI PHARMA markets Aloxi® (palonosetron hydrochloride) Injection, Dacogen ™ (decitabine) for Injection and Gliadel® (polifeprosan 20 with carmustine

MGI PHARMA Announces Positive Results from a Pivotal Phase 3 Study ...  -  Mar 21, 2007
PipelineReview.com (press release),MGI PHARMA markets Aloxi(R) (palonosetron hydrochloride) Injection, Dacogen(R) (decitabine) for Injection, and Gliadel(R) Wafer (polifeprosan 20 with

MGI PHARMA to Present at the Lehman Brothers  -  Mar 14, 2007
Business Wire (press release),MGI PHARMA markets Aloxi® (palonosetron hydrochloride) Injection, Dacogen™ (decitabine) for Injection and Gliadel® Wafer (polifeprosan 20 with carmustine

HELSINN HEALTHCARE SA Announces Patent Extension for Aloxi(R ...  -  Feb 13, 2007
netPR.pl (komunikaty prasowe),...patent term extension has been granted by the US Patent and Trademark Office for the patent covering Aloxi(R) (palonosetron hydrochloride) Injection.

MGI Pharma and Helsinn Healthcare SA Announce Patent Extension for ...  -  Feb 13, 2007
PharmaLive.com (press release),MGI PHARMA markets Aloxi(R) (palonosetron hydrochloride) Injection, Dacogen(R) (decitabine) for Injection, and Gliadel(R) Wafer (polifeprosan 20 with

MGI PHARMA Reports Fourth Quarter and Full Year 2006 Financial Results  -  Feb 8, 2007
PharmaLive.com (press release),During the fourth quarter of 2006, US sales of Aloxi(R) (palonosetron hydrochloride) Injection totaled $49.6 million compared to $67.0 million in the fourth

HELSINN HEALTHCARE SA Announces Patent Extension for Aloxi(R ...  -  Feb 13, 2007
Earthtimes.org...patent term extensionhas been granted by the US Patent and Trademark Office for the patentcovering Aloxi(R) (palonosetron hydrochloride) Injection.

MGI PHARMA to Present at the 2007 Merrill Lynch Global ...  -  Jan 31, 2007
dBusinessNews Minneapolis (press release),MGI PHARMA markets Aloxi® (palonosetron hydrochloride) Injection, Dacogen™ (decitabine) for Injection and Gliadel® Wafer (polifeprosan 20 with carmustine

MGI Pharma Announces Publication of Phase 3 Data for Saforis ...  -  18 Jan 2007
PharmaLive.com (press release),MGI PHARMA markets Aloxi(R) (palonosetron hydrochloride) Injection, Dacogen(TM) (decitabine) for Injection and Gliadel(R) Wafer (polifeprosan 20 with

JPMorgan 25th Annual Healthcare Conference  -  Jan 3, 2007
Business Wire (press release),MGI PHARMA markets Aloxi® (palonosetron hydrochloride) Injection, Dacogen™ (decitabine) for Injection and Gliadel® Wafer (polifeprosan 20 with carmustine

Helsinn Announces Positive Phase 3 Results for Aloxi(R ...  -  Dec 14, 2006
Drug Newswire (press release),...completion of two phase 3 trials of Aloxi(R) (palonosetron hydrochloride) Injection for the prevention of post-operative nausea and vomiting (PONV).

MGI PHARMA and HELSINN Announce Positive Phase 3 Results for Aloxi ...  -  Dec 14, 2006
Business Wire (press release),MGI PHARMA markets Aloxi® (palonosetron hydrochloride) Injection, Dacogen™ (decitabine) for Injection, and Gliadel® Wafer (polifeprosan 20 with carmustine

MGI PHARMA and HELSINN Announce Positive Phase 3 Results for Aloxi ...  -  Dec 15, 2006
PipelineReview.com (press release),MGI PHARMA markets Aloxi(R) (palonosetron hydrochloride) Injection, Dacogen(TM) (decitabine) for Injection, and Gliadel(R) Wafer (polifeprosan 20 with

(PRN) - Bowlin Travel Centers Report Nine-Month and Third Quarter ...  -  Dec 14, 2006
Bolsamania.com,...(PRN) - Helsinn Announces Positive Phase 3 Results for Aloxi(R)(Palonosetron Hydrochloride) Injection for the Prevention of Post Operative Nausea & Vomiting

MGI PHARMA Recognized for Innovation & Growth  Nov 2, 2006
MGI PHARMA markets Aloxi® (palonosetron hydrochloride) Injection, Dacogenâ„¢ (decitabine) for Injection and Gliadel® Wafer (polifeprosan 20 with carmustine ... -Business Wire (press release), MGI PHARMA Recognized for Innovation & Growth  Nov 2, 2006
MGI PHARMA markets Aloxi(R) (palonosetron hydrochloride) Injection, Dacogen(TM) (decitabine) for Injection and Gliadel(R) Wafer (polifeprosan 20 with ... -Genetic Engineering News (press release), MGI PHARMA Reports Third Quarter 2006 Financial Results  Oct 18, 2006
...third quarter of 2006 from $66.4 million in the third quarter of 2005, driven primarily by higher sales of Aloxi® (palonosetron hydrochloride) Injection, the ... -Business Wire (press release), MGI PHARMA to Present at the UBS Global Life Sciences Conference  Sep 19, 2006
MGI PHARMA markets Aloxi(R) (palonosetron hydrochloride) Injection, Dacogen(TM) (decitabine) for Injection and Gliadel(R) Wafer (polifeprosan 20 with ... -Business Wire

MGI PHARMA to Present at the Lazard Capital Markets Third Annual ...  -  Nov 20, 2006
Business Wire (press release),MGI PHARMA markets Aloxi® (palonosetron hydrochloride) Injection, Dacogen™ (decitabine) for Injection and Gliadel® Wafer (polifeprosan 20 with carmustine

MGI Pharma to Present at the Lazard Capital Markets Third Annual ...  -  Nov 21, 2006
PharmaLive.com (press release),MGI PHARMA markets Aloxi(R) (palonosetron hydrochloride) Injection, Dacogen(TM) (decitabine) for Injection and Gliadel(R) Wafer (polifeprosan 20 with

MGI PHARMA Announces Executive Appointments  Aug 8, 2006
MGI PHARMA markets Aloxi(R) (palonosetron hydrochloride) Injection, Dacogen(TM) (decitabine) for Injection and Gliadel(R) Wafer (polifeprosan 20 with ... -dBusinessNews Minneapolis

MGI PHARMA Reports Second Quarter 2006 Financial Results  Jul 19, 2006
...quarter of 2006 from $65.3 million in the second quarter of 2005, driven primarily by higher sales of Aloxi(R) (palonosetron hydrochloride) Injection, the ... -Business Wire

MGI PHARMA's Analyst and Investor Event to Be Webcast on July 25 ...  Jul 19, 2006
MGI PHARMA markets Aloxi(R) (palonosetron hydrochloride) Injection, Dacogen(TM) (decitabine) for Injection and Gliadel(R) Wafer (polifeprosan 20 with ... -Business Wire

MGI PHARMA Announces License Agreement with Cilag GmbH, a Johnson ...  Jul 6, 2006
MGIPHARMA markets Aloxi(R) (palonosetron hydrochloride) Injection,Dacogen(TM) (decitabine) for Injection, and Gliadel(R) Wafer(polifeprosan 20 with carmustine ... -Finanzen.net



MGI PHARMA to Present at the 2006 Bank of America Health Care ...  May 11, 2006
MGI PHARMA markets Aloxi(R) (palonosetron hydrochloride) injection and Gliadel(R) Wafer (polifeprosan 20 with carmustine implant) in the United States. ... - PharmaLive.com

US FDA Approves Dacogen(TM) (Decitabine) For Injection  May 3, 2006
MGI PHARMA markets Aloxi® (palonosetron hydrochloride) Injection and Gliadel® Wafer (polifeprosan 20 with carmustine implant) in the United States, and ... - Yahoo! News

US FDA Approves Dacogen(TM) (Decitabine) for Injection; Dacogen(TM ...  May 3, 2006
MGI PHARMAmarkets Aloxi(R) (palonosetron hydrochloride) Injection and Gliadel(R)Wafer (polifeprosan 20 with carmustine implant) in the United States,and ... - Finanzen.net

MGI PHARMA Announces Publication of Phase 3 Data for Dacogen ...  Apr 18, 2006
MGI PHARMA markets Aloxi(R) (palonosetron hydrochloride) Injection and Gliadel(R) Wafer (polifeprosan 20 with carmustine implant) in the United States. ... - PharmaLive.com

MGI PHARMA Reports First Quarter 2006 Financial Results; First ...  Apr 19, 2006
During the first quarter of 2006, US sales of Aloxi(R) (palonosetron hydrochloride) Injection totaled $63.3 million compared to $57.2 million in the first ... - Business Wire





Helsinn and Pfizer sign a license agreement for the marketing of ...  Apr 6, 2006
Ltd., announced the signing of an agreement granting Pfizer the exclusive license and distribution rights of Aloxi (Palonosetron hydrochloride), a therapy for ... - Therapeutics Daily (subscription)

MGI PHARMA Announces Initiation of Aquavan(R) Injection Pivotal ...  Mar 20, 2006
MGI PHARMA markets Aloxi(R) (palonosetron hydrochloride) Injection and Gliadel(R) Wafer (polifeprosan 20 with carmustine implant) in the United States. ... - Genetic Engineering News

Helsinn and Pfizer Laboratories (Pty) Ltd Sign a License Agreement ...  Mar 9, 2006
...the signing of an agreement granting Pfizer in South Africa, the exclusive license and distribution rights of Aloxi(R) (Palonosetron hydrochloride), a therapy ... - PR Newswire UK



Helsinn and Biovitrum Enter a License Agreement for Nordic ...  Feb 15, 2006
Sweden announce the signing of an agreement granting Biovitrum the exclusive license and distribution rights of Aloxi(R) (Palonosetron hydrochloride) in the ... - Genetic Engineering News,

Helsinn and Biovitrum Enter a License Agreement for Nordic ...  Feb 15, 2006
...company, announce the signing of an agreement granting Biovitrum the exclusive License and Distribution rights of Aloxi(R) (Palonosetron hydrochloride) in the ... - PR Newswire UK,

CORRECTING and REPLACING MGI PHARMA Reports Fourth Quarter and ...  09 Feb 2006
...company, today announced that totalrevenue for 2005 increased 43% to $279.4 million, including Aloxi(R)(palonosetron hydrochloride) injection sales of $248.5 ... - Finanzen.net

ΞΕÎ?Η ΔΗΜΟΣΙΕΥΣΗ-ΑÎ?ΑΚΟΙÎ?ΩΣΗ ΤΥΠΟΥ-PRN ...  09 Feb 2006
...which it granted THERABEL PHARMA the exclusive License and Distribution rights to distribute, market and sell Aloxi(R) (palonosetron hydrochloride) in France ... - Athens News Agency

MGI PHARMA to Present at the BIO CEO and Investor Conference  Feb 7, 2006
MGI PHARMA markets Aloxi(R) (palonosetron hydrochloride)injection and Gliadel(R) Wafer (polifeprosan 20 with carmustineimplant) in the United States. ... - Finanzen.net

MGI PHARMA to Present at the BIO CEO and Investor Conference  Feb 7, 2006
MGI PHARMA markets Aloxi(R) (palonosetron hydrochloride) injection and Gliadel(R) Wafer (polifeprosan 20 with carmustine implant) in the United States. ... - Genetic Engineering News

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional